Swiss GDP grows 0.1% in Q2 as tariff front-running eases

Switzerland's economy grew by a modest 0.1% in Q2 2025, a significant slowdown from Q1 but narrowly beating consensus expectations for a contraction, primarily driven by services offsetting industrial weakness and declining retail sales. The Swiss economy faces considerable headwinds from persistent U.S. tariffs, which could reduce GDP by 0.6% and potentially trigger a recession if the pharmaceutical industry's exemption is removed, with trade negotiations showing little progress. Amidst near-zero inflation, the Swiss National Bank is consequently anticipated to cut its policy rate by 25 basis points to -0.25% this year, likely in September, signaling further monetary easing.

Analysis

Switzerland's economy demonstrated a marked deceleration in the second quarter of 2025, with GDP growth slowing to 0.1% from 0.8% in the prior quarter. While this performance narrowly averted a forecast contraction, the underlying details reveal significant weakness, as growth in the services sector was necessary to offset contractions in industrial activity and a 0.4% decline in retail sales. The primary headwind stems from U.S. trade policy, with existing tariffs projected to reduce Swiss GDP by approximately 0.6% in the medium term. The risk profile is skewed heavily to the downside, as the removal of the current tariff exemption for pharmaceuticals could amplify the GDP impact to 1-2%, potentially precipitating a brief recession. With trade negotiations stalled and inflation approaching zero, the Swiss National Bank is expected to respond with monetary easing, with a 25 basis point rate cut to -0.25% anticipated as early as its September meeting.

Key Decisions for Investors

• Investors should exercise caution on Swiss equities with significant U.S. export exposure, particularly within the industrial and pharmaceutical sectors, due to the severe downside risks posed by unresolved trade tariffs.
• The anticipated rate cut by the Swiss National Bank creates a bearish outlook for the Swiss Franc (CHF), suggesting that investors may consider hedging their CHF exposure or exploring tactical short positions.
• Closely monitor developments in U.S.-Swiss trade negotiations, as any news regarding the tariff status, especially the pharmaceutical exemption, will be the most significant catalyst for Swiss assets and the broader economic outlook.